The effect of 7S and 19S antibodies on the primary response to Salmonella typhi antigens.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
C W Fink
Publications and source records attributed to C W Fink.
Gonococcal arthritis in children.
Explore the source record for details and available documents.
Antigen-Antibody Reactions↗
Arthritis as the presenting feature of childhood leukemia.
Explore the source record for details and available documents.
Adolescent↗
Childhood polymyositis/dermatomyositis.
Children with PM/DM differ in many respects from adults with PM/DM. The most characteristic and distinctive feature is the presence of a widespread vasculopathy. Although the pathogenesis is unknown, roles for both humoral and cell-mediated immunity have been proposed. Most intriguing is the evidence for a viral agent that is capable of precipitating an ongoing, immunologically mediated reaction damaging muscles and endothelial cells. Much remains to be discovered, however, regarding the pathogenesis of this disease.
Adolescent↗
A perineal rash in Kawasaki disease.
Explore the source record for details and available documents.
Child, Preschool↗
Overview of corticosteroid therapy in the different rheumatic diseases of childhood.
As an introduction to the workshop on corticosteroid use in childhood rheumatic disease, the types of preparations and the methods of administration are discussed. The specifics of steroid use in juvenile arthritis, dermatomyositis and systemic lupus erythematosus are given, with illustrative cases described. The use of steroids in other connective tissue diseases of childhood are briefly described.
Adolescent↗
Anterior-pituitary adrenal function of gold-treated patients with juvenile rheumatoid arthritis.
The hypothesis that gold therapy enhances endogenous cortisol secretion was tested in juvenile rheumatoid arthritis patients. The secretion of cortisol, dehydroepiandrosterone-sulfate (DHEA-S) and several peptide hormones was determined from plasma samples collected every 20 min for 24 hours. In random patients cortisol secretion was significantly greater in gold treated patients than in similar patients not receiving gold. However, when untreated patients were restudied after initiation of gold therapy, there was no significant change in cortisol secretion. Gold therapy also did not significantly alter secretion of the peptide hormones or DHEA-S. Thus, gold does not appear to influence endogenous hormone secretion.
Adolescent↗
Lymphocyte subpopulations in Kawasaki disease.
The relative percentages of subpopulations of peripheral T lymphocytes in children with Kawasaki Disease (KD) was investigated using matched antibodies directed against the T3, T4 and T8 antigens. The percentage of B cells was determined with antibodies against human surface immunoglobulins. Subjects were six children with acute KD who were compared to normal, age matched controls. The percentage of peripheral lymphocytes positive for OKT3 was 61% for KD children and 64% for controls; for OKT4 they were 41% and 44% respectively and for OKT8 both were 19%. The B cell percentages were 13% in KD and 11% in controls. Thus no abnormalities in the distribution of lymphocyte subtypes in children with KD was found. Previous studies of immune function in KD are reviewed.
Acute Disease↗
Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study.
We compared efficacy and safety of aspirin (ASA) and fenoprofen in the treatment of JRA. Ninety-nine children with JRA were given ASA or fenoprofen in a 12-wk, multicentered, double-blind, parallel study. Initial fenoprofen dosage was 900 mg/m2/d increased to 1800 mg/m2/d (3200 mg/d-max). Initial ASA dosage was 1500 mg/m2/d increased to 3000 mg/m2/d (5450 mg/d-max). Adverse reactions forced removal of 14% of ASA treated patients from the trial, whereas no fenoprofen patient was removed for this reason. Forty of 50 ASA patients, and 47 of 49 fenoprofen patients completed at least 10 wk of therapy and analysis showed that the 2 drugs were nearly identical in efficacy, but toxicity was considerably less among fenoprofen treated patients.
Arthritis, Juvenile↗
Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis. A segment I study.
The study objective was to establish a safe and efficacious dose of ketoprofen in children with JRA during a 4-week, open-labeled, non-controlled trial. Initial dosage was 100 mg/m2/d, gradually increased up to 200 mg/m2/d, not to exceed 320 mg/d. One patient was removed from the study due to hematuria. Clinical improvement was observed in 50% or more of the patients in 8 of the 15 indices assessed. Statistical improvement was detected in the number and severity of joints with pain on motion, the duration of morning stiffness, and the time required to travel 50 feet (p less than .035). Significant laboratory changes included decreases in the mean hemoglobin and hematocrit, and increases in ESR and BUN (p less than .03). Twenty patients experienced a total of 39 adverse effects and of these, 6 were judged to be attributable to ketoprofen. These preliminary data suggest ketoprofen's efficacy and safety is comparable to that of other nonsteroidal antiinflammatory drugs.
Arthritis, Juvenile↗
Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis. A segment I study.
Thirty-nine patients with JRA were treated with sodium meclofenamate (Meclomen) during a 4-wk open-labeled, non-controlled trial. Increasing doses started at 3 mg/kg/d qid, up to 7.5 mg/kg/d, not to exceed 300 mg/d. Seven patients dropped out due to adverse side effects, and 1 from inefficacy. Efficacy analysis showed statistically significant decreases in several disease indices, in particular the duration of morning stiffness. Twenty-one patients who completed the 4-wk study entered an extended open-labeled study. Nine patients completed at least 9 months of sodium meclofenamate therapy. At 9 months, these 19 showed mean decreases in all rheumatologic disease indices measured. The drug has recently been approved by the Food and Drug Administration for use in adults.
Adolescent↗
Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study.
Thirty-three patients with JRA were treated with proquazone during a 4-wk open-labeled, non-controlled trial. Increasing doses started at 400 mg/m2/d up to 800 mg/m2/d, not to exceed 960 mg/d. Oral administration was 4 times/d. One patient did not complete the study because an erythematous rash developed. Efficacy analysis showed significant decreases in the total number of active joints, the number and severity of joints with tenderness and LOM, DMS, and travel time (in all cases p less than .05). The drug appears to be similar in efficacy and safety to other NSAID that have been studied in children.
Adolescent↗
HLA associations in juvenile arthritis.
This review of the current status of HLA associations in juvenile arthritis begins with a discussion of the terms used to identify these patients and an approach for their clinical classification. The authors suggest that seven different types should be identified on the basis of clinical features and associated immunogenetic factors and that each of them should be recognized and called by a separate name. Different combinations of patients have been included in the studies performed in different cities and this fact may explain some of the observed differences in HLA associations in various reports. Results from an on-going study in Dallas are compared with published reports from Prague, Cincinnati, and Houston. HLA alleles associated with susceptibility in pauciarticular patients include certain DR and DQ alleles, one DP allele (DPB1*0201) and one HLA class I allele (HLA-A*0201). Susceptibility for polyarticular onset disease was found by the authors to be uniquely associated with DPB1*0301. Important interactions were observed between alleles at the different loci, with markedly increased odds ratios when combinations of susceptibility alleles were analyzed. The possibility that interaction between class I and class II susceptibility factors might be due to the effect of an allele at one of the TAP loci was examined by probing for polymorphic variants of the TAP1 and TAP2 genes. In addition, class I alleles associated with resistance for the development of juvenile arthritis were discussed. The main allele associated with rheumatoid arthritis (DRB1*0401) appears to be protective for the development of several forms of arthritis prevalent in children.
Arthritis, Juvenile↗
Actinomycotic splenic abscesses presenting with arthritis.
An 18-month-old Caucasian female began with a high fever. She developed swelling in one finger and one toe. Abdominal ultrasound revealed multiple abscesses in her spleen. Multiple blood culture and splenic abscess aspirations grew no pathogens. She had transient response to multiple antibiotics and splenic abscess drainage, but fever returned along with subcutaneous nodules. Culture of splenic tissue from her second splenic drainage eventually grew one organism identified as Actinomyces naeslundii. Therapy with high dose penicillin followed by amoxicillin p.o. and total splenectomy led to complete recovery.
Abscess↗